ENTITY
Samsung Biologics

Samsung Biologics (207940 KS)

326
Analysis
Health CareSouth Korea
Samsung Biologics Co.,Ltd. manufactures bio-healthcare products. The Company develops, refines, and distributes biopharmaceutical products.
more
23 Oct 2024 21:27

Samsung Biologics (207940 KS): 3Q Result Beat Expectation; Guidance Raise Amid Increasing Order Book

​Samsung Biologics reported 10% net profit growth on record high sales in 3Q24. The company raised 2024 sales growth guidance to 15–20% from...

Logo
239 Views
Share
03 Sep 2024 16:15

Trading Plays on Samsung C&T’s Holding Company Shift and Biologics Share Sell-Off

This post explores trading angles triggered by Samsung C&T’s forced holding company conversion issue, caused by the rise in Samsung Biologics'...

Logo
397 Views
Share
04 Nov 2024 07:05

KRX Foreign Holding Weekly (Nov 1st): Apr, Korzinc, Samsung Electronics, Hyundai Motor

We analyzed KRX foreign holding data for the past week and highlighted foreign holding changes in Apr, Korzinc, Samsung Electronics, Hyundai Motor.

Logo
205 Views
Share
25 Jul 2024 09:30

Samsung Biologics (207940 KS): Strong 2Q24 Result; Annual Revenue to Surpass KRW4 Trillion

​Samsung Biologics reported 34% YoY revenue growth in 2Q24. Through 2Q24, the company has secured order worth of KRW13T and is on track to exceed...

Logo
236 Views
Share
02 Jul 2024 20:12

Samsung Biologics (207940 KS): Gaining Momentum on New Approval and Contract Wins; Hold Shares

​Samsung Biologics signs $1.1B CMO contract, representing 40% of 2023 revenue. Samsung Bioepis receives FDA approval for Stelara biosimilar...

Logo
326 Views
Share
x